These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25911890)

  • 1. Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
    Shinkawa H; Uenishi T; Takemura S; Sakata C; Urata Y; Nozawa A; Hamano G; Kinoshita M; Kubo S
    Hepatogastroenterology; 2015; 62(137):169-74. PubMed ID: 25911890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
    Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
    Aoyama T; Katayama Y; Murakawa M; Asari M; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Ohkawa S; Akaike M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1235-40. PubMed ID: 25297990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.
    Aoyama T; Katayama Y; Murakawa M; Shiozawa M; Morimoto M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(137):200-6. PubMed ID: 25911897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
    Aoyama T; Katayama Y; Murakawa M; Atsumi Y; Yamaoku K; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yamamoto N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1115-20. PubMed ID: 25821166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
    Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
    BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
    Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
    J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
    Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
    Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
    Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Feasibility study of adjuvant chemotherapy with S-1 for pancreatic adenocarcinoma].
    Matsuda M; Watanabe G; Hashimoto M; Sasaki K
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):655-8. PubMed ID: 20414021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Kondo N; Nakagawa N; Sueda T
    J Surg Oncol; 2012 Aug; 106(2):174-80. PubMed ID: 22331838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
    Matsuda C; Uemura M; Nakata K; Shingai T; Nishimura J; Hata T; Ikenaga M; Takemasa I; Mizushima T; Kato T; Ikeda M; Ohue M; Murata K; Hasegawa J; Satoh T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    BMC Cancer; 2015 Jun; 15():452. PubMed ID: 26036466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
    Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
    Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
    Yeo W; Lam KO; Law AL; Lee CC; Chiang CL; Au KH; Mo FK; So TH; Lam KC; Ng WT; Li L
    Hong Kong Med J; 2017 Feb; 23(1):54-62. PubMed ID: 27966431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
    Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
    Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
    Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakagawa N; Ohge H; Sueda T
    Am J Surg; 2008 Jun; 195(6):757-62. PubMed ID: 18367131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
    Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
    Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
    Yamaue H; Satoi S; Kanbe T; Miyazawa M; Tani M; Kawai M; Hirono S; Okada K; Yanagimoto H; Kwon AH; Mukouyama T; Tsunoda H; Chijiiwa K; Ohuchida J; Kato J; Ueda K; Yamaguchi T; Egawa S; Hayashi K; Shirasaka T
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):97-102. PubMed ID: 24146260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.